List of Excipients in Branded Drug METHYLPHENIDATE HYDROCHLORIDE CD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	METHYLPHENIDATE HYDROCHLORIDE CD	methylphenidate hydrochloride	0527-4579	DIBUTYL SEBACATE
Lannett Company Inc	METHYLPHENIDATE HYDROCHLORIDE CD	methylphenidate hydrochloride	0527-4579	FD&C BLUE NO. 2
Lannett Company Inc	METHYLPHENIDATE HYDROCHLORIDE CD	methylphenidate hydrochloride	0527-4579	FERRIC OXIDE RED
Lannett Company Inc	METHYLPHENIDATE HYDROCHLORIDE CD	methylphenidate hydrochloride	0527-4579	HYPROMELLOSE

Methylphenidate Hydrochloride CD Excipient Strategy and Commercial Opportunities

Last updated: September 15, 2026

Methylphenidate hydrochloride CD is a multiparticulate, extended-release oral dosage form designed to produce an early methylphenidate exposure followed by sustained delivery. The commercial opportunity is strongest in differentiated generic or authorized-generic products that improve swallowability, food-effect control, dose flexibility, abuse-deterrence positioning, and pediatric adherence without materially increasing manufacturing complexity.

The core formulation strategy is a capsule containing drug-loaded beads with different release rates. A typical CD platform uses an immediate-release fraction and a delayed or extended-release fraction. The principal technical risks are release-profile matching, alcohol sensitivity, bead-size control, excipient variability, capsule filling, and bioequivalence against the reference product.

Scope: This analysis addresses methylphenidate hydrochloride extended-release capsules using a CD-style multiparticulate delivery system, including products associated with the Metadate CD product concept. It does not treat methylphenidate tablets, oral solutions, transdermal systems, osmotic tablets, or dexmethylphenidate products as interchangeable technologies.

What is methylphenidate hydrochloride CD?

Methylphenidate hydrochloride CD is an extended-release formulation of the central nervous system stimulant methylphenidate hydrochloride. The "CD" designation generally refers to a controlled-delivery capsule containing multiple bead populations rather than a single monolithic tablet.

Metadate CD, the reference product associated with this technology, was approved by the U.S. Food and Drug Administration in 2001 under NDA 021259. Its capsule contains immediate-release and extended-release components intended to provide therapeutic coverage during the school or work day while reducing the need for midday dosing (FDA, 2001).

How does the CD release system work?

A CD formulation normally separates the dose into at least two functional populations:

Component	Primary function	Typical formulation role
Immediate-release beads	Early plasma exposure	Rapid drug dissolution after gastric administration
Extended-release beads	Sustained exposure	Polymer-coated particles that delay or control drug release
Capsule shell	Oral delivery	Hard gelatin or hypromellose shell
Inert cores or granules	Particle substrate	Provides a uniform surface for drug layering
Seal coat	Protects drug layer	Reduces migration and improves coating uniformity
Functional coating	Controls release	Uses water-insoluble or pH-dependent polymers
Plasticizer and anti-tacking agent	Coating process control	Improves film formation and prevents agglomeration

The formulation is technically different from an osmotic methylphenidate tablet such as Concerta and from a biphasic capsule system such as Ritalin LA. These products may have overlapping clinical objectives but rely on different release mechanisms and may have different bioequivalence requirements.

What excipients protect methylphenidate hydrochloride CD performance?

The most important excipients are those controlling drug loading, bead integrity, coating permeability, and gastrointestinal release. A commercial formulation should prioritize excipients with established oral use, reliable global supply, and compendial or regulatory support.

Drug-layering excipients

Methylphenidate hydrochloride can be applied to sugar spheres or other inert multiparticulate cores using an aqueous or hydroalcoholic coating process. Povidone, hypromellose, and related film-forming materials can support adhesion and improve the uniformity of the drug layer.

Useful functions include:

• Binding methylphenidate hydrochloride to the core.
• Preventing drug loss during coating and handling.
• Improving dose uniformity across bead-size fractions.
• Reducing dusting and electrostatic segregation.
• Supporting reproducible downstream functional coating.

Povidone is commercially attractive because it is widely used, available in multiple molecular-weight grades, and familiar to regulators. Hypromellose can provide a stronger film and may improve bead mechanical strength, but grade selection affects viscosity, sprayability, and dissolution.

Functional release-controlling excipients

The extended-release fraction requires a polymer film or matrix that controls water penetration and drug diffusion. Candidate excipient families include:

• Ethylcellulose for water-insoluble diffusion membranes.
• Hypromellose for hydrophilic gel formation or film coating.
• Cellulose acetate phthalate or other pH-dependent polymers for delayed release.
• Methacrylate copolymers for tunable permeability and enteric protection.
• Polyvinyl acetate-based aqueous dispersions for sustained-release coatings.

Ethylcellulose is particularly relevant for a CD-style bead system because permeability can be adjusted through coating weight, polymer grade, pore-former concentration, and plasticizer selection. It supports a broad release window without requiring a large tablet or complex osmotic core.

A pH-dependent polymer can help place the delayed fraction later in the gastrointestinal tract. That approach may produce a sharper separation between immediate-release and delayed-release populations, but it also increases sensitivity to gastric emptying, intestinal pH, and food conditions.

Plasticizers, anti-tacking agents, and pore formers

Plasticizers such as dibutyl sebacate, triethyl citrate, or polyethylene glycol can improve film flexibility and reduce cracking. Talc or colloidal silicon dioxide may reduce tackiness during fluid-bed coating. Water-soluble pore formers can increase membrane permeability and shorten release time.

Excipient selection should avoid unnecessary complexity. Every additional coating component increases the risk of:

• Batch-to-batch dissolution variation.
• Residual solvent or moisture changes.
• Supplier qualification burdens.
• Excipient incompatibility.
• Patent or formulation overlap.
• Scale-up problems in fluid-bed processing.

The preferred commercial design is usually a two-population bead system with a small number of well-characterized excipients and a coating process controlled by measurable critical process parameters.

What excipient strategy best supports generic methylphenidate CD development?

The strongest strategy is to separate formulation functions and control each with a narrow design space.

Development objective	Preferred strategy	Main risk
Immediate release	Thin drug layer with rapidly dissolving protective film	Dose dumping or excessive early exposure
Delayed release	Ethylcellulose or pH-sensitive polymer coating	Failure to match reference lag time
Sustained release	Adjust coating weight and pore-former level	Tail drift during scale-up
Mechanical robustness	Seal coat and optimized plasticizer	Bead fracture or agglomeration
Dose flexibility	Multiple capsule strengths or sprinkle-compatible beads	Segregation and content-uniformity failure
Pediatric use	Small beads, low sensory burden, food-compatible administration	Incomplete dose delivery
Manufacturing efficiency	Aqueous coating and common bead substrate	Longer drying time and equipment capacity

A formulation team should treat dissolution as a multidimensional profile rather than a single specification. Testing should cover multiple pH conditions, agitation rates, vessel types, food states, alcohol concentrations, and capsule-opening or sprinkling conditions.

What formulations are protected by methylphenidate CD patents?

CD-style formulations may be protected by patents covering the release architecture, bead populations, coating composition, dissolution profile, dosing regimen, manufacturing process, or combination of immediate-release and extended-release fractions.

The most commercially relevant claim categories are:

1. Multiparticulate capsules containing distinct rapid- and sustained-release populations.
2. Specific ratios between immediate-release and extended-release methylphenidate.
3. Polymer-coated drug particles with defined dissolution windows.
4. Sprinkle formulations for patients unable to swallow capsules.
5. Methods of treating attention-deficit/hyperactivity disorder with once-daily dosing.
6. Manufacturing processes for drug layering, fluid-bed coating, and bead-size separation.

The original Metadate CD exclusivity period is no longer the principal barrier to entry. The product was approved in 2001, and the basic technology is now mature. Any remaining patent exposure depends on the specific reference product, Orange Book listings, continuation patents, later-developed formulations, and the claims asserted in a particular jurisdiction.

Are excipients themselves patentable?

Most conventional excipients are not commercially defensible by composition alone. Competitive protection usually comes from:

• A particular excipient ratio.
• A defined coating weight gain.
• A dissolution profile linked to a manufacturing parameter.
• A bead-size distribution.
• A food-effect limitation.
• A low-alcohol dose-dumping profile.
• A capsule that can be opened and sprinkled while preserving bioequivalence.

The best formulation patents claim measurable performance and manufacturing relationships rather than merely naming common excipients.

What is the FDA regulatory status of methylphenidate hydrochloride CD?

Methylphenidate hydrochloride is a Schedule II controlled substance in the United States. A generic CD capsule is generally submitted through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, assuming the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

Key regulatory requirements include:

• Same active ingredient and route of administration.
• Equivalent dosage form and strength.
• Comparable release characteristics.
• Bioequivalence under FDA standards.
• Controlled-substance manufacturing and distribution controls.
• Appropriate labeling for abuse, dependence, and misuse.
• Stability data supporting the proposed shelf life.

For a modified-release product, the regulatory burden is higher than for an immediate-release tablet. FDA may expect comparative fasting and fed studies, multiple-dose studies, alcohol interaction testing, and comparative in vitro dissolution across several media (FDA, 2003; FDA, 2015).

Does methylphenidate hydrochloride CD face biosimilar risk?

No. Biosimilar competition does not apply because methylphenidate hydrochloride is a chemically synthesized small molecule, not a biologic. Competitive pressure comes from ANDA-based generic capsules, reformulated methylphenidate products, authorized generics, and alternative stimulant delivery systems.

When does methylphenidate CD lose exclusivity?

The original product’s regulatory exclusivity has expired. The relevant commercial question is not whether basic Metadate CD exclusivity remains, but whether a specific product has unexpired patents, pediatric exclusivity, formulation claims, or settlement restrictions.

Exclusivity and patent timeline

Milestone	Commercial implication
2001 FDA approval of Metadate CD	Originator launch and regulatory exclusivity period
Early 2000s	Original formulation and method-of-use patent activity
Later patent expirations	Entry of generic extended-release capsules
2010s onward	Multiple generic and alternative methylphenidate technologies
Current market	Competition based primarily on cost, supply, bioequivalence, formulation differentiation, and contracting

The basic CD platform should be treated as off-patent technology unless a specific product label or Orange Book entry identifies a later unexpired patent.

How many patents cover methylphenidate hydrochloride CD?

There is no single defensible patent count for "methylphenidate hydrochloride CD" without limiting the analysis by product, jurisdiction, patent family, and claim type. A patent-family count can include expired patents, abandoned applications, continuations, process patents, and patents directed to unrelated methylphenidate dosage forms.

For commercial diligence, the relevant categories are:

• U.S. Orange Book-listed patents for the reference listed drug.
• Active U.S. formulation patents.
• Active method-of-use patents.
• Foreign counterparts in major markets.
• Pending continuation applications.
• Manufacturing patents owned by excipient, coating, or contract manufacturing partners.

The basic formulation estate is likely weak against a well-designed generic because conventional polymers, bead coating, and capsule filling are established technologies. Patent strength rises when claims require a narrow dissolution profile, a specific polymer architecture, a defined immediate-release fraction, or a manufacturing step that is difficult to design around.

Which companies are challenging methylphenidate CD products?

Generic methylphenidate competition has historically included major manufacturers such as Teva, Actavis or Allergan, Mallinckrodt, Rhodes Pharmaceuticals, Amneal, and other ANDA sponsors. The competitive field varies by strength, dosage form, supply status, and product discontinuation.

The main competitor groups are:

Competitor group	Competitive basis
Generic CD capsule sponsors	Lower price and broad pharmacy distribution
Authorized generic suppliers	Reference-equivalent product under a commercial agreement
Alternative ER capsule products	Different release architecture or dosing profile
ER tablet manufacturers	Longer duration or different pharmacokinetics
Transdermal and liquid products	Administration flexibility and pediatric positioning
Newer stimulant products	Abuse-deterrence, duration, or differentiated prodrug chemistry

The competitive threat to a new CD capsule is therefore not limited to an ANDA that copies the reference product. Prescribers and payers may substitute among several methylphenidate delivery systems.

What generic entry risks exist for methylphenidate CD?

The principal entry risk is price erosion after multiple ANDA approvals. Extended-release products often retain better pricing than immediate-release generics when manufacturing is technically demanding or when there are few reliable suppliers. That advantage can disappear if several manufacturers qualify equivalent bead-coating processes.

Commercial risks include:

• Failure to match the reference pharmacokinetic profile.
• Limited manufacturing capacity for fluid-bed coating.
• Drug shortages caused by Schedule II quota constraints.
• Capsule-shell or colorant supply interruptions.
• Low reimbursement for multiple strengths.
• Pharmacy substitution toward lower-cost generic products.
• Prescriber resistance if duration or onset differs.
• Inability to support sprinkle administration.
• Variability in controlled-substance distribution approvals.

A supplier with a robust formulation but weak controlled-substance logistics may not capture meaningful market share.

What commercial opportunities exist for methylphenidate CD excipients?

The largest opportunities are in enabling technologies rather than commodity excipient sales.

Pediatric and sprinkle-compatible formulations

Small, uniform beads that can be opened and sprinkled on soft food can improve administration for children and patients with swallowing difficulties. The formulation must preserve dose uniformity and release performance after capsule opening.

Commercial value may come from:

• Lower bead diameter.
• Reduced grittiness.
• Taste masking.
• Food compatibility.
• Improved capsule-opening instructions.
• Packaging that supports caregiver use.

Alcohol-resistant extended release

Alcohol-induced dose dumping is a major development concern for modified-release stimulants. A polymer coating that maintains controlled release in hydroalcoholic media can support regulatory differentiation and reduce safety concerns.

The opportunity is strongest where the formulation can demonstrate:

• Stable dissolution in 5%, 20%, and 40% alcohol conditions.
• No clinically meaningful increase in peak methylphenidate exposure.
• Comparable performance after food administration.
• Manufacturing robustness across commercial coating lots.

Flexible duration and dose tailoring

A CD platform can support multiple immediate-release to extended-release ratios. A sponsor could develop:

• Shorter-duration morning coverage.
• Longer school-day coverage.
• Lower-dose pediatric strengths.
• Higher-dose adult strengths.
• Combination packs or titration programs.

Such products may require new clinical or bioequivalence evidence, but the underlying manufacturing platform can be reused.

Excipient and contract manufacturing partnerships

Specialized suppliers can capture value through:

• Functional ethylcellulose dispersions.
• High-uniformity inert cores.
• Ready-to-use coating systems.
• Fluid-bed coating services.
• Controlled-substance contract manufacturing.
• Particle-size classification and capsule-filling services.

The commercial moat is strongest when the supplier controls both the excipient system and a validated process window.

How strong is the patent estate for methylphenidate CD?

The estate is generally weaker for basic multiparticulate delivery than for newer molecular or device-based delivery systems. Conventional excipients and standard fluid-bed coating are easy to substitute. A defensible estate would need claims tied to a specific performance outcome that competitors cannot reproduce without practicing the claimed combination.

Patent-strength assessment

Claim area	Relative strength	Design-around risk
Generic use of ethylcellulose	Low	High
Sugar-core drug layering	Low	High
Immediate-release plus extended-release beads	Moderate	Moderate
Specific release-ratio range	Moderate	Moderate
Narrow dissolution profile	Moderate to high	Moderate
Sprinkle-compatible controlled release	Moderate	Moderate
Alcohol-resistant profile	Moderate to high	Moderate
Novel manufacturing sequence	Moderate	Moderate
New chemical entity or prodrug	Not applicable to CD platform	Not applicable

The strongest commercial position may come from a combined package of formulation know-how, regulatory data, controlled-substance manufacturing capacity, and supply reliability rather than from a single patent.

What patent litigation and Paragraph IV risks affect methylphenidate CD?

A Paragraph IV certification can challenge an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or will not be infringed by the proposed generic. For an older CD product, the probability of a blocking patent dispute is lower than for a recently approved reformulation, but litigation risk can arise from later patents covering release profiles, dosing methods, or manufacturing processes.

Potential litigation outcomes include:

• A 30-month stay following timely patent litigation.
• Settlement with an agreed generic launch date.
• Authorized-generic supply arrangements.
• Commercial launch before litigation resolution if no listed patent blocks approval.
• At-risk launch exposing the sponsor to damages and injunctive relief.

The principal diligence issue is whether the proposed product practices a live claim. A different polymer, bead architecture, release ratio, capsule-opening method, or coating process may reduce infringement risk while preserving bioequivalence.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

1. A validated CD coating platform that reduces development time.
2. A controlled-substance manufacturing site with available capacity.
3. An authorized-generic agreement with the reference-product owner.
4. A pediatric or abuse-deterrent reformulation supported by clinical or regulatory data.

A formulation license without manufacturing know-how may have limited value because coating uniformity, bead segregation, and scale-up determine commercial performance. Conversely, a manufacturing partnership can be valuable even when patent protection is limited if it provides reliable supply and faster ANDA execution.

How does methylphenidate CD compare with other methylphenidate products?

Product type	Release technology	Main commercial advantage	Main limitation
CD capsule	Immediate-release and extended-release beads	Sprinkle potential and differentiated onset	Coating complexity
LA capsule	Biphasic bead system	Twice-daily-like profile in one dose	Different bioequivalence target
OROS tablet	Osmotic delivery	Long duration	Cannot be easily sprinkled
Immediate-release tablet	Conventional tablet	Low cost and dose flexibility	Short duration and multiple dosing
Transdermal patch	Dermal delivery	Non-oral administration	Skin reactions and application burden
Oral solution	Liquid dosing	Pediatric titration	Short duration and taste challenges

CD capsules occupy a middle position: more differentiated than immediate-release tablets, but generally less technically defensible than osmotic or transdermal systems.

Key Takeaways

• Methylphenidate hydrochloride CD is a multiparticulate extended-release capsule, not a separate chemical entity.
• The formulation’s core value comes from controlling the ratio and release behavior of immediate-release and extended-release beads.
• Ethylcellulose, hypromellose, povidone, plasticizers, pore formers, talc, and inert cores are the main excipient tools.
• Basic excipient combinations have limited patent strength; performance-based claims and manufacturing know-how offer stronger protection.
• FDA approval requires modified-release bioequivalence work, food-effect assessment, dissolution profiling, and controlled-substance compliance.
• Biosimilar risk is not applicable. The relevant threats are ANDA generics, authorized generics, alternative methylphenidate delivery systems, and supply-driven substitution.
• The most attractive commercial opportunities are sprinkle-compatible pediatric products, alcohol-resistant release systems, flexible duration profiles, and specialized coating or controlled-substance manufacturing services.
• Generic entry is likely to create price pressure unless a sponsor has differentiated administration, reliable supply, a defensible patent position, or a strong payer and pharmacy strategy.

FAQs

Can methylphenidate hydrochloride CD capsules be opened and sprinkled?

Some multiparticulate capsules are designed for opening and sprinkling, but this depends on the approved product labeling. A formulation must preserve dose uniformity and release performance after administration on soft food.

Which polymer is most suitable for methylphenidate CD extended release?

Ethylcellulose is a common starting point for a diffusion-controlled coating. Methacrylate polymers, hypromellose, and polyvinyl acetate systems may offer better control for specific dissolution targets.

Is methylphenidate CD interchangeable with Concerta?

No. Concerta uses an osmotic extended-release tablet, while a CD capsule uses multiparticulate beads. Substitution depends on FDA product-specific equivalence determinations and applicable state pharmacy rules.

Does a new excipient create market exclusivity for a methylphenidate CD product?

Usually not. An excipient alone rarely creates meaningful exclusivity. Commercial protection is more likely to arise from a patentable formulation combination, a manufacturing process, regulatory exclusivity, or a differentiated clinical profile.

What is the highest-value development feature for a new methylphenidate CD product?

A robust pediatric sprinkle formulation combined with predictable food and alcohol performance is likely to create more commercial value than a minor change in conventional excipient composition.

References

1. U.S. Food and Drug Administration. (2001). Metadate CD (methylphenidate hydrochloride) extended-release capsules prescribing information.
2. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: General considerations.
3. U.S. Food and Drug Administration. (2015). Guidance for industry: Bioequivalence studies for drug products submitted under an ANDA: General principles.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs.
6. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
7. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.